T315I-mutated myeloid sarcoma

T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.

The early stage of chronic myeloid leukemia is triggered by the tyrosine kinase Bcr-Abl. Imatinib mesylate, a selective inhibitor of Bcr-Abl, has been successful in chronic myeloid leukemia clinical trials, but short-lived remissions are usually observed in blast crisis patients. Sequencing of the BCR-ABL gene in relapsed patients revealed a set of mutants that mediate drug resistance. Previous...

Myeloid Sarcoma

Temporal bone myeloid sarcoma.

A 69-year-old male previously diagnosed with acute myeloblastic leukemia secondary to myelodysplastic syndrome (LMA with dysplasia, karyotype 46XY, and no cytogenetics abnormalities) refractory to treatment (hydroxyurea, cytarabine, mitoxantrone, and azacitidine) presented with right-side otalgia, otorrhea, and deafness with 2 months progression. He had been treated with oral ciprofloxacin, ear...

Temporal Bone Myeloid Sarcoma

Myeloid sarcoma is a rare condition that's caused by the aggregation of immature myeloid cells in leukemic patients. Myeloid sarcoma occurring in the temporal bone more frequently involves the mastoid bone than is the case for metastatic lesions arising from non-systemic malignancies. The disease is difficult to diagnose when it presents with symptoms that mimic otomastoiditis. However, an earl...

Donor Cell Myeloid Sarcoma

Donor cell derived malignancies are a rare and interesting complication of allogeneic bone marrow transplantation. We present a case of a 56-year-old male with donor cell myeloid sarcoma of the stomach and myocardium.